MS
MIRM icon

Maven Securities’s Mirum Pharmaceuticals MIRM Stock Holding History

Maven Securities’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,000
Closed -$1.82M – 1250
2020
Q4 		$1.82M Buy
+100,000
New +$1.97M 0.18% 148

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Maven Securities's MIRM Position: Q1 2021 in Review

Maven Securities sold out of Mirum Pharmaceuticals (MIRM) in Q1 2021, closing a stake of 100,000 shares — an estimated $1.82M sold.

Maven Securities first reported a position in MIRM in Q4 2020 and held it in 1 quarter. The position peaked at $1.82M in Q4 2020. 61 funds tracked by Wall St. Rank hold MIRM as of Q1 2021.

  • Maven Securities reported no remaining Mirum Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Maven Securities sold 100,000 Mirum Pharmaceuticals shares in Q1 2021, an estimated $1.82M.
  • Maven Securities first reported a position in Mirum Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Maven Securities's Mirum Pharmaceuticals position peaked at $1.82M in Q4 2020.
  • 61 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.